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Abstract
Adrenomedullin (AM) and calcitonin gene-related peptide (CGRP) are potent vasodilator peptides 
and serve as ligands for the G-protein coupled receptor (GPCR) calcitonin receptor-like receptor 
(CLR/Calcrl). Three GPCR accessory proteins called receptor activity-modifying proteins 
(RAMPs) modify the ligand binding affinity of the receptor such that the CLR/RAMP1 
heterodimer preferably binds CGRP, while CLR/RAMP2 and CLR/RAMP3 have a stronger 
affinity for AM. Here we determine the contribution of each of the three RAMPs to blood pressure 
control in response to exogenous AM and CGRP by measuring the blood pressure of mice with 
genetic reduction or deletion of the receptor components. Thus, the cardiovascular response of 
Ramp1−/−, Ramp2+/−, Ramp3−/−, Ramp1−/−/Ramp3−/− double-knockout (dKO), and Calcrl+/− 
mice to AM and CGRP were compared to wildtype mice. While under anesthesia, Ramp1−/− male 
mice had significantly higher basal blood pressure than wildtype males; a difference which was 
not present in female mice. Additionally, anesthetized Ramp1−/−, Ramp3−/−, and Calcrl+/− male 
mice exhibited significantly higher basal blood pressure than females of the same genotype. The 
hypotensive response to intravenously injected AM was greatly attenuated in Ramp1−/− mice, and 
to a lesser extent in Ramp3−/− and Calcrl+/− mice. However, Ramp1−/−/Ramp3−/− dKO mice 
retained some hypotensive response to AM. These results suggest that the hypotensive effect of 
AM is primarily mediated through the CLR/RAMP1 heterodimer, but that AM signaling via CLR/
RAMP2 and CLR/RAMP3 also contributes to some hypotensive action. On the other hand, 
CGRP’s hypotensive activity seems to be predominantly through the CLR/RAMP1 heterodimer. 
With this knowledge, therapeutic AM or CGRP peptides could be designed to cause less 
hypotension while maintaining canonical receptor-RAMP mediated signaling.
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1. Introduction
Adrenomedullin (AM) is a circulating multi-functional peptide and a known vasodilator [1]. 
AM is a member of the calcitonin peptide family along with amylin and calcitonin gene-
related peptide (CGRP), a peptide considered to be one of the most potent endogenous 
vasodilators [2]. Circulating levels of AM are increased during many forms of 
cardiovascular disease [3] including heart failure where AM plays a cardioprotective role.
Exogenous administration of AM has beneficial hemodynamic/renal effects, improved 
cardiac output, and overall survival rates [4–8]. AM imparts these cardioprotective actions 
via numerous biological functions including vasodilation, diuresis, and natriuresis which are 
further augmented by inhibition of the renin-angiotensin-aldosterone system [4–7]. In 
addition, exogenous AM is known to play a protective role in lung injury and sepsis, perhaps 
through its anti-inflammatory and anti-microbial properties [9,10]. Given the beneficial 
properties of AM peptide, it may serve as a candidate therapeutic agent. However, the 
vasodilatory effects of AM may cause undesirable side-effects or be contraindicated in some 
patients. Therefore, a more thorough understanding of the mechanisms underlying the 
vasodilatory action of AM may allow for the development of effective therapeutics.
AM and CGRP are ligands for the G-protein-coupled receptor known as calcitonin receptor-
like receptor (CLR = protein name; Calcrl = gene name). In the endoplasmic reticulum, CLR 
associates with one of three receptor activity modifying proteins (RAMPs) that confer ligand 
specificity and binding affinity [11]. On their own, CLR and RAMPs rarely migrate to cell 
surface, but as a complex they translocate to the cell surface to interact with their respective 
ligands. Historically, the CLR/RAMP1 heterodimer is known as the CGRP receptor given its 
high ligand binding affinity for CGRP. CLR/RAMP2 and CLR/RAMP3 are known as the 
AM1 and AM2 receptors, respectively since AM is considered the primary ligand [12]. 
However, these receptor-RAMP heterodimers are not exclusively selective. AM can bind and 
activate the CGRP receptor and CGRP activates AM1 and AM2, though with lower potency 
than at the respective cognate receptors [13]
A 50% reduction in endogenous AM levels do not affect basal blood pressure in genetically 
heterozygous AM mice [14]. However, a bolus injection of AM causes dose-dependent 
hypotension [7,15]. The effects of exogenous AM on blood pressure have previously been 
examined using several genetic mouse models [16–18] and receptor inhibitors [19–21], but 
the relative contribution of each heterodimer to AM- and CGRP-induced hypotension has 
still not been fully explored or comparatively evaluated. Thus, the simultaneous examination 
of a comprehensive collection of genetic knockout mouse models for RAMPs and CLR 
could provide insight into the respective roles that CLR/RAMP1, CLR/RAMP2, and CLR/
RAMP3 heterodimers play in the hypotensive responses to AM and CGRP.
In the current study, we examine the blood pressure and heart rate of mice under isoflurane 
anesthesia following intravenous injections of AM or CGRP. Gene disruption mouse models 
of Calcrl, Ramp1, Ramp2, and Ramp3 were previously generated and are examined along 
with strain and age-matched wild type (WT) mice. Mice lacking Calcrl [22,23] and RAMP2 
[18,23,24] are embryonic lethal, so these lines were examined as heterozygotes (+/−).
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2. Methods
2.1. Mice
All mice used in this study were between 8–16 weeks of age and are on the 129/S6-SvEv-
TC1 background. The generation of Ramp1, Ramp2, Ramp3 and Calcrl knockout mice were 
previously described [22,24,25]. All experiments were approved by the Institutional Animal 
Care and Use Committee of the University of North Carolina at Chapel Hill.
2.2. Blood pressure measurements
Mice were anesthetized with 2% isoflurane gas. The left carotid artery was exposed and a 
suture was placed around the distal end of the artery. Then a loosely tied suture was placed 
around the proximal end. An occluding ligature was placed on the proximal end of the artery 
to minimize bleeding during catheter insertion. A small incision was made in the isolated 
carotid artery near the distal end and a SciSense mouse blood pressure transducer was 
inserted. The proximal occlusion was then removed as the transducer was advanced into the 
artery retrograde to the ascending aorta and tied in placed. Measurements were recorded 
through a Scisense ADVantage PV control unit onto Labscribe 2 software (iWorx Systems, 
Inc.).
2.3. Peptides
AM and CGRP peptides (Phoenix Pharmaceuticals) were dissolved in saline solution (0.9% 
Sodium Chloride, Hospira). A volume of 0.05 ml was used for all vehicle control and 
experimental dosage intravenous injections, and an additional 0.02 ml of saline was injected 
to clear the catheter of peptide. In experiments where two identical doses of AM were 
injected 20 min apart (Fig. 2), 12 nmol/kg of AM peptide was used per dose. In experiments 
where sequentially increasing doses of AM or CGRP were injected 5 min apart, 0.12 
nmol/kg of peptide was used for the first dose, 1.2 nmol/kg for the second dose, 12 nmol/kg 
for the third dose, and 120 nmol/kg for the fourth and final dose.
2.4. Data and statistical analysis
Basal blood pressure was defined as the mean arterial pressure (MAP) during the 2 min prior 
to the first injection. Using Labscribe 2 software, MAP was calculated by applying a 
smoothing function to blood pressure charts, averaging each data point (1000/sec) by all 
neighboring data points within 1.5 s. Changes in blood pressure following injection were 
determined by identifying the lowest MAP measurement after injection and calculating the 
percent change from baseline blood pressure. Percent change was used, rather than reporting 
absolute blood pressure, because significant differences in basal blood pressure exist 
between mouse lines and sexes. Statistical analyses were performed using the Student’s t-
test. Differences with P < 0.05 were deemed statistically significant.
In experiments where mice received two 12 nmol/kg doses of AM 20 min apart (Fig. 2) each 
genotype was n ≥ 8 when both sexes are combined and n ≥ 4 for each sex alone. Specifically, 
WT mice were n = 12 (7 males, 5 females), Ramp1−/− mice were n = 8 (4 males, 4 females), 
Ramp1−/−/Ramp3−/− dKO mice were n = 11 (5 males, 6 females), Ramp3−/− mice were n = 
14 (8 males, 6 females), Ramp2+/− mice were n = 8 (4 males, 4 females), and Calcrl+/− mice 
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were n = 8 (4 males, 4 females). In experiments where four sequentially increasing doses 
(0.12 nmol/kg to 120 nmol/kg) of peptide were injected 5 min apart, mice receiving AM 
were n = 5 (2 males, 3 females) per genotype, and mice receiving CGRP were n = 4 (2 
males, 2 females) per genotype. Baseline blood pressure and heart rate were measured under 
anesthesia, prior to dosing, and calculations in Table 1 were made from all the mice used in 
the experiments just previously described.
3. Results
3.1. Basal blood pressure and heart rate
The basal blood pressures of anesthetized male and female mice were compared to wildtype 
(WT) mice of the same sex. Ramp1−/−, Ramp1−/−/Ramp3−/− dKO, and Calcrl+/− males were 
each found to have significantly higher basal blood pressure than their sex-matched WT 
counterparts (Table 1). We also analyzed for sexual dimorphism within each genotype. WT 
control males showed a modestly elevated basal blood pressure than WT females, but this 
difference was not statistically significant. In contrast, Ramp1−/−, Ramp1−/−/Ramp3−/−, 
Ramp3−/−, and Calcrl+/− males all showed significantly elevated blood pressures compared 
to female mice of the same genotype. We also examined baseline heart rate, and found no 
significant differences to sex-matched WT mice; however we did find a reduction in 
Calcrl+/− female heart rate compared to Calcrl+/− males (Table 1).
3.2. Effect of exogenous AM and CGRP on blood pressure
Using WT mice, 12 nmol/kg of AM was empirically determined to be an appropriate dose to 
elicit a robust and measureable decline in blood pressure that was large enough to observe 
any attenuation that may occur in the genetic knockout models. To ensure proper insertion of 
the catheter prior to administering AM, each mouse was initially injected with saline 
solution (vehicle) and no measurable response was observed following vehicle injection 
(data not shown). Following intravenous injection of 12 nmol/kg of AM, WT mouse blood 
pressure declined by 13.0 ± 1.2% (n = 14) and remained depressed with a gradual recovery 
in the following minutes. An identical dose, administered 20 min later to the same animal, 
caused an additional drop of 11.3 ± 0.8% (n = 12) (Figs. 1 and 2A, B). This effect was 
attenuated in Ramp1−/− mice, and to a lesser extent, in Ramp3−/− and Calcrl+/− mice. The 
first injection of AM in Ramp1−/− mice reduced blood pressure by about 52% of what was 
observed in WT animals (6.2 ± 1.0% n = 8, p < 0.0001). However, the second AM dose 
resulted in only a slight drop in mean pressure (1.7 ± 0.8% n = 7, p < 0.0001) with 4 out of 7 
mice showing no measurable change in blood pressure. In Ramp1−/−/Ramp3−/− dKO mice, 
similar results were observed for the first (6.1 ± 1.6% n = 11, p < 0.0001) and second (0.8 
± 0.4% n = 11, p < 0.0001) AM injection, with 7 out of 11 mice showing no change in blood 
pressure on the second dose. Examination of heart rate following AM injections did not 
show any significant difference between genotypes (data not shown).
Results for Ramp1−/− and Ramp1−/−/Ramp3−/− dKO mice were similar when separately 
examining males and females (Fig. 2C–F). Compared to WT, Ramp3−/− mice showed a 
significantly diminished decline in blood pressure following the first injection (9.3 ± 1.4% n 
= 14, p < 0.05), but the second injection (10.1 ± 0.6% n = 14, ns) showed no significance 
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and was similar to the first. Subsequent analysis by sex of Ramp3−/− mice showed no 
difference in AM responsiveness to their WT counterparts. Ramp2+/− mice behaved 
similarly to WT for both the first (12.3 ± 1.2% n = 8, ns) and second (12.6 ± 2.0% n = 7, ns) 
AM injections. The decline in blood pressure was diminished by 29% in Calcrl+/− mice with 
the first AM dose (9.2 ± 1.0% n = 8, p < 0.05) and by 28% after the second AM dose (8.1 
± 0.7% n = 8, p < 0.05). Calcrl+/− males, but not Calcrl+/− females, showed a significantly 
attenuated response to exogenous AM compared to WT controls. However, when directly 
compared, there was statistically no difference between Calcrl+/− males and females.
To determine how AM-induced hypotension contrasts with CGRP-induced hypotension, 
sequentially increasing doses ranging from 0.12 nmol/kg to 120 nmol/kg of AM (Fig. 3A) or 
CGRP (Fig. 3B) were administered 5 min apart. This experiment revealed that AM is 
between 10 and 100 fold less potent that CGRP in eliciting a hypotensive response in WT 
mice. However, in Ramp1−/− mice the CGRP response is effectively eliminated (p = 0.003, 
paired T-test of Ramp1−/− to WT at 12 nmol/kg CGRP); these mice retain a response to AM, 
though the magnitude of response is reduced by ~50% compared to WT (p = 0.002, paired 
T-test of Ramp1−/− to WT at 12 nmol/kg AM) (Fig. 3A, B). Knockout of Ramp3, either 
alone or in combination with Ramp1, does not appear to impart any significant effect on the 
hypotensive response to either AM (p = 0.390, paired T-test of Ramp3−/− to WT at 12 
nmol/kg) or CGRP (p = 0.988, paired T-test of Ramp3−/− to WT at 12 nmol/kg). 
Additionally, the highest dose of 120 nmol/kg CGRP was relatively ineffective in WT, 
Ramp3−/−, Ramp2+/−, and Calcrl+/− mice perhaps due to receptor internalization and 
desensitization. To determine if the desensitization effect caused by CGRP was able to alter 
the hypotensive response to AM, we repeated the experiment, but gave 120 nmol/kg AM 
instead of CGRP at the last dose (Fig. 3C). AM still gave a hypotensive response (Fig. 3C), 
but at a similar level observed in AM-only treated Ramp1−/− mice (Fig. 3A).
4. Discussion
4.1. Sexual dimorphisms in basal blood pressure
Although not statistically significant in the WT group, we find a consistent trend of higher 
blood pressure in males over females across all genotypes (Table 1). With Ramp2+/− being 
the only exception, this sexually dimorphic effect is observed in all mice tested, and appears 
to be imparted primarily by an increase in male blood pressure, rather than a significant 
reduction in female blood pressure. This suggests that males may be more susceptible to 
disruptions in CLR-mediated signaling which may contribute to the development or 
exacerbation of a disease state. In fact, in a chronic hypertension model [26], male mice with 
a 50% reduction in endogenous AM have increased cardiac hypertrophy and renal damage 
which were not observed in female mice [14]. Furthermore, evidence by our group using the 
same chronic hypertension model showed a similar sex dependent effect on cardiac 
hypertrophy in Ramp3−/− mice [27].
Previous studies on CGRP KO mice have provided contrasting evidence on the effect of 
endogenous CGRP in baseline blood pressure. CGRP KO mice generated by Lu et al. show 
no change in baseline blood pressure [28], whereas CGRP KO mice on a hybrid 129/Sv x 
C57BL/6 background exhibit hypertension [29]. Indeed, sex differences in blood pressure 
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are highly strain dependent. For example, C57BL/6J female mice have higher blood pressure 
than their male counterparts, whereas 129S1/SvImJ, a strain more closely related to the one 
used in this study (129S6/SvEv-Tac1), have the opposite relationship [30]. It’s unclear if 
disrupted signaling via CLR would show similar or contrasting effects on blood pressure in 
other genetic strains, but our observations suggest that within the genetic diversity of the 
human population some individuals may have altered blood pressure based on differences in 
CLR-mediated signaling. Previous findings in humans showing that infusion of CGRP 
antagonists have no effect on resting blood pressure seem to suggest otherwise [31], but a 
short agonist treatment may not be analogous to the complete and consistent effect of 
genetically altered CLR-mediated signaling.
4.2. Effect of exogenous AM and CGRP on blood pressure
In the present study, Ramp1−/−, Ramp2+/−, Ramp3−/−, Ramp1−/−/Ramp3−/− dKO and 
Calcrl+/− mice were systematically and comparatively examined to determine the effects of 
exogenous AM and CGRP on blood pressure and heart rate. Ramp2+/− and Calcrl+/− mice 
are used because of the embryonic lethality of Ramp2−/− and Calcrl−/− mice. Calcrl+/− mice 
showed a modest, but significant attenuation in AM-induced hypotension. This is an 
expected outcome, considering that the biological effects of AM are mediated via signaling 
through heterodimers with the common CLR receptor. What has not been clear is to what 
extent each of the RAMPs is involved in modulating the effect of AM on blood pressure 
when dimerized with CLR. We demonstrate here that Ramp1−/− mice showed a significantly 
diminished blood pressure response following an intravenous injection of AM. This has 
previously been observed in sodium pentobarbital anesthetized Ramp1−/− mice and fits with 
previous observations that the hypotensive effect of exogenous AM is attenuated in the 
presence of the CLR/RAMP1 antagonist peptide, CGRP(8–37) [16,19]. However, it should 
be noted that despite AM and CGRP both causing a hypotensive response via CLR/RAMP1, 
it has been shown in small human thymic arteries [32] and sheep coronary artery [33] that 
AM causes vasodilation via a nitric oxide-guanylyl cyclase mechanism, whereas CGRP was 
found to signal through a cAMP-dependent mechanism [32]. Additionally, results from 
endothelial denudation experiments suggest that AM primarily induces vasodilation through 
the endothelium, whereas CGRP does not [32]. So, common signaling through CLR/
RAMP1 does not preclude AM and CGRP from signaling via divergent downstream 
pathways that may be cell type dependent.
The blood pressure response after the second dose of AM in Ramp1−/− mice is significantly 
more diminished than the response elicited by the first injection (Fig. 2A, C, and E). This is 
likely due to desensitization and internalization of occupied receptors during the initial dose 
[34]. Compared to WT, Ramp1−/− mice exhibited over a 50% reduction of hypotension 
caused by the initial dose of AM and a greater than 80% reduction caused by the second 
dose of AM. This suggests that the AM-induced hypotension is primarily mediated through 
the CLR/RAMP1 heterodimer, which has historically been considered the CGRP receptor. 
However, even at an affinity of 1–2 orders of magnitude lower than CGRP, the affinity of 
AM for CLR/RAMP1 still has physiological effects [35,36]. With the CLR/RAMP1 
heterodimer established as a primary mediator of the hypotensive response, it stands to 
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reason that AM causes a hypotensive response similar to CGRP at a dosage of 1–2 orders of 
magnitude higher, given their relative affinities.
Since a modest reduction of blood pressure still occurs following AM treatment in Ramp1−/− 
mice, it would be expected that the remainder of signaling would be mediated through the 
CLR/RAMP2 and CLR/RAMP3 heterodimers. Direct examination of RAMP2 via genetic 
deletion is precluded by embryonic lethality of the full knockout mouse, and Ramp2+/− mice 
do not show an attenuated response to AM, perhaps due to a sufficient amount of RAMP2 
remaining to generate a normal blood pressure response. So to further elucidate the relative 
contributions of these heterodimers to the AM-induced hypotension, Ramp1−/−/Ramp3−/− 
dKO mice were examined, leaving RAMP2 as the only RAMP expressed. This analysis did 
not reveal any significant difference in AM-induced hypotension between Ramp1−/−/
Ramp3−/− dKO and Ramp1−/− mice, and Ramp1−/−/Ramp3−/− dKO mice still exhibited a 
hypotensive response. Since RAMP2 is the only RAMP expressed in the Ramp1−/−/
Ramp3−/− dKO, this suggests that the hypotensive response of AM is mediated through both 
CLR/RAMP1 and CLR/RAMP2, whereas the effect of CGRP is almost exclusively 
mediated by CLR/RAMP1. This is further supported by our finding that desensitization to 
CGRP after sequentially increasing doses did not fully attenuate the hypotensive response 
caused by AM (Fig. 3C), and the observation that Calcrl+/− mice do not seem any more 
desensitized than WT mice to CGRP after treatment (Fig. 3B) suggests that it is likely CLR-
RAMP1 depletion, but not CLR-RAMP2/3 depletion, that is the cause for this effect. We did 
see a significant attenuation of hypotension to AM after the first injection in Ramp3−/− mice, 
but this was only observed after pooling data from both sexes and was not recapitulated by 
the second injection.
Interpretation of the results from mice deficient in RAMP2 and RAMP3 is complicated by 
the fact that loss of a high affinity binding receptor increases available ligand for CLR/
RAMP1 which would presumably enhance the hypotension in an initial AM dose. 
Additionally, with the removal of competition for available CLR in the endoplasmic 
reticulum there may be increased availability of CLR for RAMP1 heterodimerization which 
could lead to increased surface CLR/RAMP1. A third layer of influence could reside in 
compensatory alterations in relative gene expression levels of non-targeted RAMPs and CLR 
in the knockout models. For example, we previously showed that Ramp3−/− mice have 
increased Calcrl mRNA expression [27], but it is not clear if this would result in more CLR/
RAMP1 on the cell surface.
Direct examination of the hypotensive effects of AM in the absence of the CLR/RAMP2 
heterodimer is precluded by the embryonic lethality of Ramp2−/− mice. In this study, 
Ramp2+/−mice showed no significant differences compared to WT mice. However, mice 
overexpressing RAMP2 in smooth muscle cells have an enhanced hypotensive effect to 
exogenous AM following intravenous injection [17], which supports a clear role for the 
CLR/RAMP2 heterodimer in the hypotensive response to AM. More recently, we have 
developed a genetic mouse model in which the expression of Ramp2 is deleted in all cells, 
except cells expressing the endothelial VE-cadherin promoter [37], thus imparting an ability 
of some of these animals to survive embryonic lethality. These mice show marked systemic 
hypotension, once again supporting a role for the CLR/RAMP2 heterodimer in regulating 
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basal blood pressure. Unfortunately, because Ramp2 and Ramp3 reside very closely to each 
other on mouse chromosome 11, the generation of a RAMP2/3 dKO or RAMP triple-KO 
animal remains challenging. As such, we cannot fully eliminate the possibility that some of 
the AM-induced hypotension may be mediated via a non-canonical pathway or mechanism. 
Nevertheless, these results along with previously published observations suggest that either 
or both CLR/RAMP2 and CLR/RAMP3 heterodimers play an important role in mediating 
the hypotensive response to AM.
4.3. Therapeutic implications as evident from disease models
Several lines of evidence suggest that both AM and CGRP have cardioprotective effects that 
may be therapeutically valuable. In a DOCA-salt hypertension model, CGRP/calcitonin 
knockout mice are more vulnerable to hypertension-induced heart and kidney damage [38] 
which may be attributed to its role as a suppressor of inflammatory mediators [16]. In a 
transverse aortic constriction model of heart disease, CGRP knockout mice had reduced 
survivability and a worsened cardiac phenotype [39]. Inversely, infusion of CGRP has been 
shown to improve circulation in patients with heart disease [40,41]. When Adm+/− mice 
were given an AngII/high-salt treatment, they had worsened perivascular fibrosis and intimal 
hyperplasia in the coronary arteries compared to WT mice, possibly via inhibition of 
oxidative stress [42]. In a rat model of heart failure, acute administration of AM increased 
cardiac output and reduced right ventricular systolic pressure only in failing hearts. 
Subsequently, in patients with heart failure, intravascularly administered AM improved 
cardiac index and reduced pulmonary arterial pressure only in individuals experiencing heart 
failure. Additionally, administration of AM in the ApoE−/− mouse model of spontaneous 
atherosclerosis reduced the appearance of atherosclerotic lesions [43].
In addition to their cardioprotective effects, these peptides have a wide range of other 
functions including in the reproductive system [44], the lymphatic vasculature [23], and the 
nervous system [45], and so their therapeutic potential must be evaluated in the context of 
broader systemic functions [46]. Given the wide range of actions of these peptides, 
continuing to study how AM and CGRP signal to produce these actions may help in the 
development of improved therapeutic peptides that could be tailored to the specific disease 
indication.
5. Conclusions
This work highlights the importance of CLR-RAMP signaling in AM-induced hypotension 
and establishes CLR/RAMP1 as the primary, but not sole, mediator of the effect. These 
results further suggest CLR/RAMP2 and CLR/RAMP3 contribute to the remaining 
hypotensive effect, while CGRP induced hypotension signaling remains specific for the 
CLR/RAMP1 heterodimer. While the sex of an individual has an established contribution to 
differences in blood pressure, this works shows no obvious sexual dimorphism in the 
response to infusion of AM or CGRP. We hope that these contributions provide an improved 
understanding of AM/CGRP peptide effects on blood pressure regulation, with important 
implications for future therapeutic strategies.
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Fig. 1. 
Representative blood pressure charts from a single mouse receiving a 12 nmol/kg dose of 
AM converted to a percentage of baseline pressure (black), and the smooth line calculated 
from the chart (orange). Time 0 marks the time of AM injection. (For interpretation of the 
references to colour in this figure legend, the reader is referred to the web version of this 
article.)
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Fig. 2. 
Change in blood pressure following 12 nmol/kg intravenous injections of AM. Injections 
were spaced 20 min apart. (a,c,e) Maximum acute change in blood pressure after two 
injections, 20 min apart, for (a) all mice, (c) males, and (e) females. (b,d,f) Mean blood 
pressure of the first 3 min following the first injection for (b) all mice, (d) males, and (f) 
females. For all analyses, n ≥ 8 for all genotypes and n ≥ 4 per sex of each genotype. 
Significance to WT after the same injection (*) is shown. *P < 0.05, ** P < 0.01, ***P < 
0.001.
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Fig. 3. 
The change in blood pressure following sequentially increasing doses of (a) AM and (b) 
CGRP from 0.12 nmol/kg to 120 nmol/kg body weight. (c) WT mice were given 
sequentially increasing doses of CGRP up to 12 nmol/kg, same as panel b, but the 4th and 
final dose given was 120 nmol/kg of AM (n = 4) instead of CGRP (n = 4). All doses were 
administered 5 min apart. Each genotype receiving AM were n = 5 mice composed of 3 
females and 2 males. Each genotype receiving CGRP were n = 4 mice composed of 2 
females and 2 males. The effect of AM and CGRP on blood pressure across genotypes and 
dosages were each significant by two-way analysis of variance with P-values < 0.0001. ** P 
< 0.01, Student’s t-test.
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